Aurora kinase inhibitors in preclinical and clinical testing

Author： Cheung Chun Hei Antonio Coumar Mohane Selvaraj Hsieh Hsing-Pang Chang Jang-Yang

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.18, Iss.4, 2009-04, pp. : 379-398

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Aurora kinase inhibitors: identification and preclinical validation of their biomarkers

By Carpinelli Patrizia Moll Jürgen

Expert Opinion on Therapeutic Targets, Vol. 12, Iss. 1, 2008-01 ,pp. : 69-80

Informa Healthcare

Access to resources Recommend Favorite

Aurora kinase inhibitor patents and agents in clinical testing: an update (2009 –– 10)

By Cheung Chun Hei Antonio Coumar Mohane Selvaraj Chang Jang-Yang Hsieh Hsing-Pang

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 6, 2011-06 ,pp. : 857-884

Informa Healthcare

Access to resources Recommend Favorite

Dawn of Aurora kinase inhibitors as anticancer drugs

By Doggrell Sheila A

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 9, 2004-09 ,pp. : 1199-1201

Informa Healthcare

Access to resources Recommend Favorite

Aurora-B Kinase Inhibitors for Cancer Chemotherapy

Mini Reviews in Medicinal Chemistry, Vol. 8, Iss. 14, 2008-12 ,pp. : 1514-1525

Bentham Science Publishers

Access to resources Recommend Favorite

Vertex inhibitors of Aurora-2, glycogen synthase kinase-3 and Src kinase

Expert Opinion on Therapeutic Patents, Vol. 14, Iss. 3, 2004-03 ,pp. : 439-443

Informa Healthcare

Access to resources Recommend Favorite